The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treating Uveitis with Adalimumab Improves Quality of Life

Treating Uveitis with Adalimumab Improves Quality of Life

May 2, 2017 • By Marilynn Larkin

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Treatment of uveitis with adalimumab is linked with “clinically meaningful” differences in quality of life compared with treatment with placebo, new research shows.

You Might Also Like
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Adalimumab + Methotrexate Effective for Uveitis in JIA
  • Adalimumab Lowers Risk of Uveitic Flare

Dr. John Sheppard of Eastern Virginia Medical School in Norfolk, Va., tells Reuters Health, “Regardless of underlying etiology or lack thereof, uveitis can have a profoundly adverse effect upon an individuals’ physical, emotional, work, avocational and social functioning in everyday life.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“This study utilizes a validated quality of life questionnaire to demonstrate that adalimumab-treated patients with noninfectious uveitis experience significant and functionally meaningful improvements in vision-related quality of life, compared with those who received placebo,” he says.

As reported in JAMA Ophthalmology, online April 20, Dr. Sheppard and colleagues conducted post-hoc analyses of one clinical trial that involved 217 adults (about half women, with mean age 43) with active noninfectious intermediate uveitis, posterior uveitis and panuveitis, and a second trial involving 226 individuals (60% women, with mean age 43) with inactive disease.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

All patients completed the National Eye Institute Vision Function Questionnaire (NEI VFQ-25), which assesses the effect of visual impairment from the patient’s perspective. Scores range from 0–100, with higher scores indicating better vision-related quality of life.

Patients were randomized to an 80 mg subcutaneous loading dose of adalimumab followed by 40 mg adalimumab every other week, or placebo, for 80 weeks.

In the active disease trial, treatment benefit was assessed for the first time at Week 6. Outcomes for this group were changes in the NEI VFQ-25 from the best state achieved prior to week six to the final visit. That change was −1.30 for adalimumab and −5.50 for placebo (P=0.01).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In the inactive disease trial, treatment benefit was assessed as the difference between NEI VFQ-25 scores from the baseline visit to the final (or early termination) visit. The change in that group was 3.36 for adalimumab and 1.24 for placebo (P=0.16).

In both trials, longitudinal analyses showed a significant difference overall in NEI VFQ-25 between adalimumab and placebo of 3.07 (scores of 74.15 vs. 71.08, respectively) for the active disease trial and 4.66 (82.39 vs. 77.73) in the inactive disease trial.

The authors say their findings suggest “that adalimumab is associated with statistically significant and clinically meaningful improvements in patient-reported visual functioning for patients with noninfectious intermediate uveitis, posterior uveitis and panuveitis.”

Editorialist Dr. Bryn Burkholder of Johns Hopkins University School of Medicine in Baltimore, tells Reuters Healt, “[Although] scores on the NEI VFQ-25 may not completely reflect the complex ways in which uveitis can affect a patient’s life, the study … makes a strong argument that treatment with adalimumab can improve vision-related quality of life in some clinically meaningful ways.”2

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: adalimumab, patient care, quality of life, Uveitis

You Might Also Like:
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients
  • Adalimumab + Methotrexate Effective for Uveitis in JIA
  • Adalimumab Lowers Risk of Uveitic Flare
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)